Clinical trials: Personality Disorders
Borderline Personality Disorder
Cognitive Reappraisal Training for Borderline Personality
Previous work by the study group convinced the study team to pursue development of focused cognitive reappraisal training as a novel approach to treatment of BPD, either as stand-alone treatment or in concert with evidence-based…
- Trial name
- BPD (NCT04967222)
- Testing
- Cognitive Reappraisal by Distancing, Control Downregulate Condition
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Borderline Personality Disorder
A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder
There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants…
- Trial name
- NCT04100096
- Testing
- Brexpiprazole
- Where
- 77 sites in United States, Spain and 1 more
- Volunteers
- 332 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Borderline Personality Disorder
Brexpiprazole in Borderline Personality Disorder
The primary objective of the proposed study is to evaluate the safety and efficacy of Brexpiprazole in adults with borderline personality disorder (BPD).
- Trial name
- NCT03418675
- Testing
- Rexulti
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Chicago
Borderline Personality Disorder, Emotional Problem
Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder
Offspring of mothers with Borderline Personality Disorder (BPD) are at serious risk for developing mental illness at every stage of their life, and yet little is known about how this risk is transmitted.
- Trial name
- NCT03060902
- Testing
- Dialectical Behavior Therapy Skills
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Oregon
Pulmonary Function; Newborn, Abnormal, Infant Wheeze
Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function
Vitamin C supplementation (500 mg per day) given to pregnant women who can not quit smoking will improve the pulmonary function tests in their offspring measured at 3 months of age.
- Conditions
- Pulmonary Function; Newborn, Abnormal, Infant Wheeze, In-utero Nicotine, Second Hand Smoke
- Trial name
- VCSIP (NCT01723696)
- Testing
- Vitamin C +prenatal vitamin
- Where
- 2 sites in United States
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Major Depressive Disorder, Dysthymia
Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
- Conditions
- Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Borderline Personality Disorder
- Trial name
- NCT01189812
- Testing
- Lithium Carbonate, Citalopram
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Columbia Northwest Pharmaceuticals
Borderline Personality Disorder
Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder
This study examines the effects of 12 months of dialectical behavior therapy (DBT) for subjects with borderline personality disorder on aggression, anger and emotional dysregulation.
- Trial name
- NCT00467038
- Testing
- Dialectical Behavior
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Borderline Personality Disorder
Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)
The Primary objective of this study is to evaluate Seroquel XR in the treatment of borderline personality disorder (BPD). As in many initial randomized control trials, the study will be of relatively short duration - 8 weeks - to…
- Trial name
- NCT00880919
- Testing
- quetiapine extended-release
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- University of Minnesota
Cervical Neoplasia
Feasibility of Delphi Screener for Cervical Cytology
The aim of this study is to see whether a new self-sampling device, the Delphi Screener (Delphi Devices, Scherpenzeel, Netherlands), can be used for cervical cancer screening.
- Trial name
- NCT00702208
- Testing
- Delphi Screener
- Where
- United States
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Columbia University
Substance Use, Psychopathy
The Impact of Psychopathic Traits on the Efficacy of a Substance Use Intervention
Substance use among criminal offenders constitutes a major public health problem and is tied to negative consequences for offenders, their families, and their communities.
- Trial name
- NCT01532934
- Testing
- motivational enhancement therapy, standard care
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Rochester
Borderline Personality Disorder
Ketamine in Borderline Personality Disorder
The purpose of this study is to test the potential of the rapid-acting anti-depressant ketamine to decrease suicidality in Borderline Personality Disorder (BPD).
- Trial name
- NCT03395314
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Yale University
Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development
Maternal Adversity, Vulnerability and Neurodevelopment
Maternal Adversity Vulnerability and Neurodevelopment (MAVAN) project is a prospective community-based, pregnancy and birth cohort of Canadian mother-child dyads.
- Conditions
- Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Infant Development, Infant Behavior
- Trial name
- MAVAN (NCT03434457)
- Where
- Canada
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Borderline Personality Disorder
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young…
- Trial name
- NCT01103180
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Chicago
Borderline Personality Disorder
Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.
- Trial name
- NCT00533117
- Testing
- Fluoxetine, Dialectical Behavior Therapy, Supportive psychotherapy
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- New York State Psychiatric Institute
Borderline Personality Disorder
Isolating Mechanisms in the Treatment of Borderline Personality Disorder
Borderline personality disorder (BPD) is a commonly occurring, severe, and costly condition that interferes greatly with quality of life.
- Trial name
- NCT03408860
- Testing
- Countering Emotional Behaviors Module from Unified Protocol
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Boston University Charles River Campus
Borderline Personality Disorder
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
- Trial name
- NCT04932291
- Testing
- vafidemstat
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 211 people
- Sponsor
- Oryzon Genomics S.A.
Borderline Personality Disorder (BPD)
Researching the Effectiveness of a Alivis, a Digital Health Application for Borderline Personality Disorder
This randomized controlled trial (RCT) with 470 patients diagnosed with Borderline Personality Disorder (BPD) aims to investigate the effectiveness of the unguided digital therapeutic alivis for patients with BPD as defined in…
- Trial name
- REVALDI-BPD (NCT06601907)
- Testing
- alivis
- Where
- Germany
- Volunteers
- 286 people
- Sponsor
- Gaia AG
Borderline Personality Disorder
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
Participants will be randomized to either Mifepristone 600mg once daily for seven days or Placebo tablet once daily for seven days. Rating scales, vital signs, cortisol levels will be collected for evaluation.
- Trial name
- NCT01212588
- Testing
- mifepristone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Indiana University